SinoMab BioScience Ltd (HKG: 3681), a biotech firm based in Hong Kong, has announced the first patient dosing in a Phase Ib clinical study for SM17, a pioneering drug for atopic dermatitis (AD). The study is designed to evaluate the safety, tolerability, and pharmacokinetics of SM17, along with preliminary efficacy, and has thus far reported no adverse events.
SM17 is a first-in-class therapeutic that targets the suppression of Th2 immune responses by binding to IL-17RB on Type 2 Innate Lymphoid cells (ILC2s), thereby blocking the inflammatory cascade triggered by interleukin-25 (IL-25). Preclinical studies have demonstrated that SM17 is as effective as JAK1 inhibitors in treating AD in mice models. Phase Ia trials have indicated that SM17 offers a safety profile that is consistent and acceptable in both American and Chinese populations.- Flcube.com
